Factor analysis in predominantly severe COPD: identification of disease heterogeneity by easily measurable characteristics.

[1]  Bernadette A. Thomas,et al.  Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[2]  J. Connett,et al.  Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[3]  Ciro Casanova,et al.  The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. , 2011, American journal of respiratory and critical care medicine.

[4]  D. Postma,et al.  A new perspective on optimal care for patients with COPD. , 2011, Primary care respiratory journal : journal of the General Practice Airways Group.

[5]  M Cazzola,et al.  Symptom variability in patients with severe COPD: a pan-European cross-sectional study , 2010, European Respiratory Journal.

[6]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[7]  Edwin K Silverman,et al.  Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.

[8]  Edwin K Silverman,et al.  Chronic obstructive pulmonary disease phenotypes: the future of COPD. , 2010, American journal of respiratory and critical care medicine.

[9]  M. V. Lopez Varela,et al.  Sex-related differences in COPD in five Latin American cities: the PLATINO study , 2010, European Respiratory Journal.

[10]  D. Caillaud,et al.  Clinical COPD phenotypes: a novel approach using principal component and cluster analyses , 2010, European Respiratory Journal.

[11]  T. Welte,et al.  Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.

[12]  S. Rennard,et al.  Efficacy and Tolerability of Budesonide/Formoterol in One Hydrofluoroalkane Pressurized Metered-Dose Inhaler in Patients with Chronic Obstructive Pulmonary Disease , 2009, Drugs.

[13]  Wim Timens,et al.  The pathology of chronic obstructive pulmonary disease. , 2009, Annual review of pathology.

[14]  S. Rennard,et al.  Efficacy and Safety of Budesonide and Formoterol in One Pressurized Metered-Dose Inhaler in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease , 2008, Drugs.

[15]  D. Mannino,et al.  Global burden of COPD: risk factors, prevalence, and future trends , 2007, The Lancet.

[16]  C. Mathers,et al.  Projections of Global Mortality and Burden of Disease from 2002 to 2030 , 2006, PLoS medicine.

[17]  N. Pride,et al.  Proposal for a multidimensional staging system for chronic obstructive pulmonary disease: Respir Med 2005;99:1546–54 , 2006 .

[18]  N. Pride,et al.  Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. , 2005, Respiratory medicine.

[19]  A. Hansell,et al.  Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. , 2005, Chest.

[20]  A. Sood,et al.  Obesity Is Associated with Bronchial Hyper-Responsiveness in Women , 2005, The Journal of asthma : official journal of the Association for the Care of Asthma.

[21]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[22]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[23]  R. Sansores,et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[24]  P. Jones,et al.  Health status measurement in chronic obstructive pulmonary disease , 2001, Thorax.

[25]  D. Coultas,et al.  Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. , 2000, Archives of internal medicine.

[26]  D. Postma,et al.  Inflammatory cell number and mediators in bronchoalveolar lavage fluid and peripheral blood in subjects with asthma with increased nocturnal airways narrowing. , 1995, The Journal of allergy and clinical immunology.

[27]  D. Postma,et al.  Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group. , 1994, Thorax.

[28]  P. Jones,et al.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.

[29]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.

[30]  T. Clark,et al.  Diurnal rhythm of asthma. , 1987, Chest.

[31]  B. Manly.  Multivariate Statistical Methods : A Primer , 1986 .